InflaRx NV
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying InflaRx stock, predicting a potential increase to $4.33 per share.
Financial Health
InflaRx NV is struggling with low revenue and profitability, indicating potential challenges ahead.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IFRX
German Stocks Soaring
Discover a carefully selected collection of German companies that have been dramatically outperforming their western counterparts. Our team of professional analysts has identified these standout stocks as Germany's economy shows promising signs of growth in 2025.
Published: May 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage focus
Progress and value depend heavily on trial outcomes and regulatory milestones; this creates opportunity but also significant binary risk.
Pipeline-driven moves
Share performance tends to follow study readouts and approvals, so updates can cause sharp moves; diversification helps manage this volatility.
Market and funding
As a small-cap biotech, financing and partnerships matter for execution; funding gaps or delays can materially affect development timelines.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
